Purpose: Our study aimed to determine the impact of a novel technique of anesthesia administration on the clinical outcomes and complications in geriatric patients with severe systemic disease undergoing hip surgery. Methods: We retrospectively identified patients aged > 65 years with severe systemic disease that was a constant of life [American Society of Anesthesiologists (ASA) IV] who underwent surgery for hip fracture between January 2018 and January 2020. The patients were divided into two groups: Group I [fascia iliaca compartment block plus propofol-based total intravenous anesthesia (FICB + TIVA)] and Group II [general anesthesia (GA)]. The primary outcomes were 30-day and 1-year mortality. The secondary outcomes included length of hospital stay, length of intensive care unit (ICU) stay, postoperative morbidity, Visual Analog Scale score, and consumption of analgesics. Results: There was no significant difference in the 30-day mortality (5 vs. 3.8%, p = 0.85) and 1-year mortality (15 vs. 12%, p = 0.73) between the groups. Group I had significantly lower ICU requirements (p = 0.01) and shorter lengths of ICU stay (p < 0.001) and hospital stay (p < 0.001). Moreover, a smaller proportion of patients in Group I required postoperative morphine or oral opiates. Conclusion: Geriatric patients who underwent hip surgery under FICB + TIVA required fewer ICU admissions, shorter lengths of ICU and hospital stay, and had lesser postoperative opioid consumption than those who were under GA. Hence, we recommend the novel FICB + TIVA technique for hip fracture surgery in geriatric patients with poor general health status and high surgical risks (ASA IV).

Chronic periprosthetic joint infection (PJI) presents a major challenge in knee arthroplasty, with varying success rates reported for two-stage exchange arthroplasty (EA) and a lack of consensus on managing failures from such procedures. This study evaluated repeat two-stage EA outcomes for knee PJI after initial treatment failure to identify the risk factors for reimplantation unsuitability and reinfection. We analyzed 114 patients who underwent repeat EA for chronic knee PJI between 2010 and 2018. From an initial cohort of 1,351 patients, we excluded 231: 18 for incomplete records or protocol non-compliance and 213 for prior revisions. Among the remaining 1,119 patients, 150 experienced reinfection. After excluding 36 who did not undergo repeat EA, the final cohort comprised 114 patients. Outcomes were evaluated using Delphi-based consensus success criteria as follows: healed wounds, no further infection interventions, and no PJI-related mortality. In our study, 34.2% of the patients did not proceed with reimplantation due to reinfection or ongoing infection, which was influenced by factors such as high Charlson Comorbidity Index scores, recurrence of a microorganism, and shorter intervals between initial arthroplasty and reinfection. Among the reimplanted patients, 44.0% underwent further revision for rereinfection. Kaplan-Meier analysis of 1,119 initial, 75 repeat, and 24 re-repeat two-stage cases revealed 5-year infection-free survival rates of 93, 72, and 43%, respectively. This study identified significant reinfection risks in patients who have repeated infections by the same microorganisms, persistent PJI, or multiple spacer redo procedures. A 39.5% rereinfection rate, including 12 amputations and a 15.8% mortality rate, was observed in this series. This study underscores the effectiveness of first-time two-stage EA for knee PJI and notes the challenges and lower success rates of subsequent attempts. This emphasizes the importance of identifying high-risk patients for tailored treatment plans and setting realistic expectations of outcomes. III.

Managing periprosthetic joint infections (PJIs) in orthopedic surgery is particularly challenging, especially with two-stage exchange arthroplasty. This st

Antibiotic-loaded bone cement (ALBC) plays a pivotal role in infection prevention and treatment related to musculoskeletal surgery. The release efficacy of antibiotics from ALBC is closely tied to its surface area, yet little is known about the effective release depth. To investigate the relationship between surface area, volume, and antibiotic elution, spheric ALBC specimens with consistent outer diameters but different internal metal sphere diameters were prepared. Two vancomycin doses were utilized in ALBC specimens with an outer diameter of 35 mm: high (4 g) and low (1 g). Each dosage group included five specimens containing embedded metal spheres with diameters of 15, 25, 29, 32, or 33 mm. The resulting shell-like ALBC specimens had thicknesses of 10 mm, 5 mm, 3 mm, 1.5 mm, or 1 mm, respectively. The specimens were immersed in sterile phosphate buffer solution, and antibiotic elution was measured at designated sampling times (1, 3, 6, 10, 24, 48, 72, and 168 hours). Methylene blue was employed to visualize penetration depth. Vancomycin elution did not display statistically significant differences between high- and low-dose groups. In both groups, specimens with 1 mm thickness exhibited a higher vancomycin release efficiency (high-dose group: 18560±5474 μg, 6.7%; low-dose group: 2017±419 μg, 2.6%), decreasing sharply in thicker ALBC specimens. Methylene blue penetration depth showed no apparent difference between high-dose and low-dose groups. ALBC thickness does not significantly impact antibiotic elution, while surface area and antibiotic dose exert notable effects. These in vitro findings offer potential applications in clinical treatments for musculoskeletal infections.